Therapeutics Company Secures FDA Clearance For Solid Tumor Clinical Trial

In a significant leap towards transforming cancer care, TransCode Therapeutics, Inc., a beacon of innovation in the oncology sphere, has received the much-anticipated nod from the U.S. Food and Drug Administration (FDA) to initiate a groundbreaking Phase 1/2 clinical trial. This trial is set to explore the potential of TTX-MC138, a promising therapeutic candidate, in the battle against advanced solid tumors. This development not only marks a pivotal milestone for TransCode but also ignites hope for countless patients grappling with metastatic diseases. $Transcode Therapeutics(RNAZ.US)$